Krystal Biotech, Inc.

NasdaqGS:KRYS Voorraadrapport

Marktkapitalisatie: US$5.1b

Krystal Biotech Inkomsten in het verleden

Verleden criteriumcontroles 2/6

Krystal Biotech's earnings have been declining at an average annual rate of -0.4%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been growing at an average rate of 101.5% per year. Krystal Biotech's return on equity is 12.6%, and it has net margins of 63.7%.

Belangrijke informatie

-0.4%

Groei van de winst

3.3%

Groei van de winst per aandeel

Biotechs Groei van de industrie17.0%
Inkomstengroei101.5%
Rendement op eigen vermogen12.6%
Nettomarge63.7%
Volgende winstupdate04 Nov 2024

Recente prestatie-updates uit het verleden

Krystal Biotech's (NASDAQ:KRYS) Earnings Might Be Weaker Than You Think

May 13
Krystal Biotech's (NASDAQ:KRYS) Earnings Might Be Weaker Than You Think

Recent updates

Krystal Biotech: Q4 Catalysts Expected With VYJUVEK Revenue Growth Pressing On

Oct 14

Krystal Biotech: High Valuation Merits Caution Ahead Of Q2 Earnings (Rating Downgrade)

Jul 31

Krystal Biotech's (NASDAQ:KRYS) Earnings Might Be Weaker Than You Think

May 13
Krystal Biotech's (NASDAQ:KRYS) Earnings Might Be Weaker Than You Think

Krystal Biotech's Future Brightens With Vyjuvek's Robust Launch

Feb 28

Krystal Biotech: Ready For Launch

Feb 20

We Think Krystal Biotech (NASDAQ:KRYS) Can Easily Afford To Drive Business Growth

Jan 02
We Think Krystal Biotech (NASDAQ:KRYS) Can Easily Afford To Drive Business Growth

Companies Like Krystal Biotech (NASDAQ:KRYS) Can Afford To Invest In Growth

Sep 06
Companies Like Krystal Biotech (NASDAQ:KRYS) Can Afford To Invest In Growth

Are Investors Undervaluing Krystal Biotech, Inc. (NASDAQ:KRYS) By 46%?

Aug 08
Are Investors Undervaluing Krystal Biotech, Inc. (NASDAQ:KRYS) By 46%?

We Think Krystal Biotech (NASDAQ:KRYS) Can Afford To Drive Business Growth

May 17
We Think Krystal Biotech (NASDAQ:KRYS) Can Afford To Drive Business Growth

We're Hopeful That Krystal Biotech (NASDAQ:KRYS) Will Use Its Cash Wisely

Jan 30
We're Hopeful That Krystal Biotech (NASDAQ:KRYS) Will Use Its Cash Wisely

Krystal Biotech cleared to file EU marketing application for rare skin disease therapy

Sep 22

We Think Krystal Biotech (NASDAQ:KRYS) Can Afford To Drive Business Growth

Aug 30
We Think Krystal Biotech (NASDAQ:KRYS) Can Afford To Drive Business Growth

Krystal Biotech: Solid Performance, Let's Keep Holding

Aug 18

Krystal Biotech GAAP EPS of -$1.10 misses by $0.07

Aug 08

Krystal gets FDA nod to start trial of gene therapy KB407 for cystic fibrosis

Aug 01

Krystal Biotech: High Potential, Buy-At-Dips Stock

May 25

We're Hopeful That Krystal Biotech (NASDAQ:KRYS) Will Use Its Cash Wisely

Apr 20
We're Hopeful That Krystal Biotech (NASDAQ:KRYS) Will Use Its Cash Wisely

Krystal Biotech: The Future Looks More And More Derisked

Feb 21

Krystal Biotech Establishes Proof Of Concept With STAR-D Platform; Opens Door For More Skin Indications

Nov 30

Krystal Biotech: A Buy Ahead Of Their Pivotal DEB P3 Trial Readout

Sep 27

Here's Why We're Not Too Worried About Krystal Biotech's (NASDAQ:KRYS) Cash Burn Situation

Sep 25
Here's Why We're Not Too Worried About Krystal Biotech's (NASDAQ:KRYS) Cash Burn Situation

Companies Like Krystal Biotech (NASDAQ:KRYS) Are In A Position To Invest In Growth

Jun 17
Companies Like Krystal Biotech (NASDAQ:KRYS) Are In A Position To Invest In Growth

Opbrengsten en kosten

Hoe Krystal Biotech geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.


Inkomsten en omzetgeschiedenis

NasdaqGS:KRYS Opbrengsten, kosten en inkomsten (USD Millions )
DatumInkomstenInkomstenG+A UitgavenR&D-uitgaven
30 Jun 2416610610249
31 Mar 24965710045
31 Dec 2351119846
30 Sep 239-309846
30 Jun 230-1409447
31 Mar 230-1358645
31 Dec 220-1407942
30 Sep 220-1306941
30 Jun 220-1155935
31 Mar 220-1045131
31 Dec 210-704228
30 Sep 210-583225
30 Jun 210-522724
31 Mar 210-432121
31 Dec 200-321518
30 Sep 200-271217
30 Jun 200-22915
31 Mar 200-20716
31 Dec 190-19616
30 Sep 190-17614
30 Jun 190-16612
31 Mar 190-1359
31 Dec 180-1148
30 Sep 180-936
30 Jun 180-1135
31 Mar 180-1024
31 Dec 170-823
30 Sep 170-713
30 Jun 170-211

Kwaliteitswinsten: KRYS has a high level of non-cash earnings.

Groeiende winstmarge: KRYS became profitable in the past.


Analyse vrije kasstroom versus winst


Analyse van de winstgroei in het verleden

Winsttrend: KRYS has become profitable over the past 5 years, growing earnings by -0.4% per year.

Versnelling van de groei: KRYS has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Winst versus industrie: KRYS has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).


Rendement op eigen vermogen

Hoge ROE: KRYS's Return on Equity (12.6%) is considered low.


Rendement op activa


Rendement op geïnvesteerd vermogen


Ontdek sterk presterende bedrijven uit het verleden